Thrombosis form
|
Thrombosis form
|
Thrombosis form
|
Thrombosis form
|
Thrombosis form
|
Thrombosis form
|
Total Case (n=83) | Control (n=160) | P-Value | |
PTE (n=48) | DVT (n=9) | AMI (n=17) | CVA (n=4) | Arterial thrombosis (n=5) | P-Value | ||||
Gender-male-n (%) | 15(31.3) | 4(44.4) | 3(17.7) | 3(75.0) | 2(40.0) | 0.219 | 27(32.5) | 76(47.5) | 0.025* |
Age-year-Mean(SD) | 59.7(17.9) | 62.8(22.3) | 64.8(15.1) | 695(18.3) | 64(34.8) | 0.172 | 61.8(18.9) | 59.0(17.6) | 0.239 |
Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) | Age group-n (%) |
<18 | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0.606 | 0(0) | 1(0.63) | 0.871 |
18-29 | 2(4.2) | 1(11.1) | 0(0) | 0(0) | 1(20.0) | 4(4.82) | 7(4.38) | ||
30-59 | 22(45.8) | 3(33.3) | 9(52.9) | 1(25.0) | 1(20.0) | 36(43.4) | 65(40.6) | ||
60≤ | 24(50.0) | 5(55.5) | 8(47.1) | 3(75.0) | 3(60.0) | 43(51.8) | 87(54.3) | ||
ESRD-n (%) | 1(2.1) | 0(0) | 2(11.8) | 0(0) | 0(0) | 0.520 | 3(3.6) | 13(8.1) | 0.179 |
COPD-n (%) | 1(2.1) | 0(0) | 0(0) | 0(0) | 0(0) | 0.904 | 1(1.2) | 6(3.8) | 0.261 |
Malignancy-n (%) | 0(0) | 0(0) | 1(5.9) | 0(0) | 0(0) | 0.507 | 1(1.2) | 10(6.3) | 0.073 |
CVA-n (%) | 3(6.3) | 0(0) | 1(5.9) | 1(25.0) | 1(20.0) | 0.376 | 6(7.2) | 8(5.0) | 0.479 |
DM-n (%) | 9(18.8) | 0(0) | 6(35.3) | 2(50.0) | 3(60.0) | 0.045* | 20(24.1) | 37(23.1) | 0.865 |
IHD-n (%) | 10(20.8) | 2(22.2) | 6(35.3) | 1(25.0) | 2(40.0) | 0.324 | 21(25.3) | 25(15.6) | 0.068 |
PTE-n (%) | 1(2.1) | 0(0) | 0(0) | 0(0) | 0(0) | 0.935 | 1(1.2) | 1(0.63) | 0.635 |
Smoking-n (%) | 5(10.4) | 2(22.2) | 2(11.8) | 1(25.0) | 0(0) | 0.761 | 10(12.1) | 17(10.6) | 0.738 |
CBR-n (%) | 39(81.3) | 7(77.8) | 15(88.2) | 0(0) | 0(0) | 0.643 | 70(84.3) | 101(63.1) | 0.001* |
RBR-n (%) | 21(43.7) | 5(55.6) | 4(23.5) | 0(0) | 5(20.0) | 0.056 | 31(37.4) | 83(51.9) | 0.031* |
Anticoagulation-n (%) | |||||||||
No anticoagulation | 23(47.9) | 7(77.8) | 16(94.1) | 4(100) | 5(100) | 0.001* | 55(66.3) | 32(20.0) | <0.0001* |
Prophylactic dose | 18(37.5) | 2(22.2) | 0(0) | 0(0) | 0(0) | 0.011* | 20(24.1) | 97(60.3) | <0.0001* |
Intermediate dose | 1(2.1) | 0(0) | 0(0) | 0(0) | 0(0) | 0.947 | 1(1.2) | 11(6.9) | 0.053 |
Therapeutic dose | 6(12.5) | 0(0) | 1(5.9) | 0(0) | 0(0) | 0.587 | 7(8.4) | 20(12.5) | 0.339 |
Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 | Chi2 test for categorical variable and independent t-test for a continuous variable were significant if P-value< 0.05 |